The cost-effectiveness of 23-valent pneumococcal vaccine in Catalonia, Spain

被引：0
|
作者：
Plans-Rubió, P [1 ]
机构：
[1] Dept Sanitat Catalonia, Barcelona, Spain
来源：
VALUE IN HEALTH | 2003年 / 6卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)61921-3
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：754 / 754
页数：1
相关论文
共 50 条
  • [41] ALLERGIC HYPERSENSITIVITY TO THE 23-VALENT PNEUMOCOCCAL VACCINE: A CASE REPORT
    McCormick, T.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2011, 107 (05) : A68 - A68
  • [42] Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in Brazilian elderly
    Simonsen, V
    Brandao, AP
    Brandileone, MCC
    Yara, TI
    Di Fabio, JL
    Lopes, MH
    Jacob, W
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2005, 38 (02) : 251 - 260
  • [43] Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales
    Andrews, Nick J.
    Waight, Pauline A.
    George, Robert C.
    Slack, Mary P. E.
    Miller, Elizabeth
    VACCINE, 2012, 30 (48) : 6802 - 6808
  • [44] Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older
    Vila-Corcoles, Angel
    Ochoa-Gondar, Olga
    Guzman, Jorge A.
    Rodriguez-Blanco, Teresa
    Salsench, Elisabet
    Fuentes, Cruz M.
    BMC INFECTIOUS DISEASES, 2010, 10
  • [45] Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review
    Cornelius Remschmidt
    Thomas Harder
    Ole Wichmann
    Christian Bogdan
    Gerhard Falkenhorst
    BMC Infectious Diseases, 16
  • [46] Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older
    Angel Vila-Corcoles
    Olga Ochoa-Gondar
    Jorge A Guzmán
    Teresa Rodriguez-Blanco
    Elisabet Salsench
    Cruz M Fuentes
    BMC Infectious Diseases, 10
  • [47] Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients
    Breiman, RF
    Keller, DW
    Phelan, MA
    Sniadack, DH
    Stephens, DS
    Rimland, D
    Farley, MM
    Schuchat, A
    Reingold, AL
    ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (17) : 2633 - 2638
  • [48] Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review
    Remschmidt, Cornelius
    Harder, Thomas
    Wichmann, Ole
    Bogdan, Christian
    Falkenhorst, Gerhard
    BMC INFECTIOUS DISEASES, 2016, 16
  • [49] ASSESSING THE COST-EFFECTIVENESS (CE) OF VACCINATING THE ELDERLY AND AT-RISK ADULTS WITH THE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) OR NO VACCINATION (NOVAC) IN THE UK
    Jiang, Y.
    Gauthier, A.
    Keeping, S. T.
    Carroll, S. M.
    VALUE IN HEALTH, 2012, 15 (07) : A396 - A397
  • [50] Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Denmark compared with PPV23
    Olsen, Jens
    Schnack, Henrik
    Skovdal, Mette
    Vietri, Jeffrey
    Mikkelsen, Malene Buch
    Poulsen, Peter Bo
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 1240 - 1254
12345